AFP and hepatocellular carcinoma: Although α-fetoprotein (AFP) is the most often used screening biomarker in clinical practice for early HCC detection, predicting tumor recurrence, and monitoring the oncological treatment, its poor sensitivity and specificity make it an unsatisfactory marker [4].